Literature DB >> 16709991

Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.

Esse N Menson1, A Sarah Walker, Mike Sharland, Carole Wells, Gareth Tudor-Williams, F Andrew I Riordan, E G Hermione Lyall, Diana M Gibb.   

Abstract

OBJECTIVE: To measure the extent of underdosing of antiretroviral drugs in children.
DESIGN: Multicentre cohort study.
SETTING: Clinical centres in hospitals in the United Kingdom and Ireland in the collaborative HIV paediatric study (CHIPS). PARTICIPANTS: 615 HIV infected children aged 2-12 years receiving antiretrovirals. MAIN OUTCOME MEASURES: Doses relative to weight and height compared with current recommended doses in 2004 European guidelines.
RESULTS: The CHIPS cohort of 934 children comprises 80% of diagnosed HIV infected children in the UK and Ireland between January 1997 and March 2005, of which 66% (615) aged 2-12 years were prescribed antiretrovirals. Actual doses standardised to weight or surface area varied widely across individual drugs, antiretroviral class, and calendar time, with children underdosed (prescribed less than 90% of current recommended doses) from 6-62% child time at risk. Three serious issues in prescribing antiretrovirals, which may also be relevant to paediatric prescribing in general, were identified. Firstly, dosing was inadequate before incorrect recommendations at licensing were later revised when important pharmacokinetic results emerged. Secondly, guidelines stating dosage alternatives (by weight/surface area) for the same drug led to different and inconsistent doses. And, thirdly, ongoing growth was not adjusted for.
CONCLUSIONS: Largely inadvertently, HIV infected children in the United Kingdom and Ireland have been underdosed with antiretrovirals, highlighting problems applicable throughout paediatric prescribing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709991      PMCID: PMC1463938          DOI: 10.1136/bmj.332.7551.1183

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  16 in total

1.  Clinical trials in children: problems and pitfalls.

Authors:  R E Kauffman
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

2.  Unlicensed and off label prescription of drugs to children: population based cohort study.

Authors:  Geert W 'T Jong; Ingo A Eland; Miriam C J M Sturkenboom; John N van den Anker; Bruno H Ch Stricker
Journal:  BMJ       Date:  2002-06-01

3.  Current evidence for the use of paediatric antiretroviral therapy--a PENTA analysis. Paediatric European Network for the Treatment of AIDS Steering Committee.

Authors:  M Sharland; D Gibb; C Giaquinto
Journal:  Eur J Pediatr       Date:  2000-09       Impact factor: 3.183

4.  A drug dosage table is a useful tool to facilitate prescriptions of antiretroviral drugs for children in Thailand.

Authors:  M Ponnet; K Frederix; W Petdachai; D Wilson; A Eksaengsri; R Zachariah
Journal:  Int J STD AIDS       Date:  2005-06       Impact factor: 1.359

5.  Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.

Authors:  P Krogstad; A Wiznia; K Luzuriaga; W Dankner; K Nielsen; M Gersten; B Kerr; A Hendricks; B Boczany; M Rosenberg; D Jung; S A Spector; Y Bryson
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

Review 6.  Antiretroviral pharmacokinetics in the paediatric population: a review.

Authors:  Jennifer R King; David W Kimberlin; Grace M Aldrovandi; Edward P Acosta
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

Authors:  S L Gortmaker; M Hughes; J Cervia; M Brady; G M Johnson; G R Seage; L Y Song; W M Dankner; J M Oleske
Journal:  N Engl J Med       Date:  2001-11-22       Impact factor: 91.245

8.  Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry.

Authors:  M de Martino; P A Tovo; M Balducci; L Galli; C Gabiano; G Rezza; P Pezzotti
Journal:  JAMA       Date:  2000-07-12       Impact factor: 56.272

9.  Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

Authors:  S E Starr; C V Fletcher; S A Spector; F H Yong; T Fenton; R C Brundage; D Manion; N Ruiz; M Gersten; M Becker; J McNamara; L M Mofenson; L Purdue; S Siminski; B Graham; D M Kornhauser; W Fiske; C Vincent; H W Lischner; W M Dankner; P M Flynn
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

10.  Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

Authors:  Catherine Litalien; Albert Faye; Alexandra Compagnucci; Carlo Giaquinto; Lynda Harper; Diana M Gibb; Evelyne Jacqz-Aigrain
Journal:  Pediatr Infect Dis J       Date:  2003-01       Impact factor: 2.129

View more
  33 in total

Review 1.  Children and HIV/AIDS: from research to policy and action in resource-limited settings.

Authors:  Joanna Orne-Gliemann; Renaud Becquet; Didier K Ekouevi; Valériane Leroy; Freddy Perez; François Dabis
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

2.  Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.

Authors:  Bhavna H Chohan; Kenneth Tapia; Sarah Benki-Nugent; Brian Khasimwa; Musa Ngayo; Elizabeth Maleche-Obimbo; Dalton Wamalwa; Julie Overbaugh; Grace John-Stewart
Journal:  AIDS Res Hum Retroviruses       Date:  2015-04-22       Impact factor: 2.205

3.  Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island.

Authors:  Tanya Rogo; Allison K DeLong; Philip Chan; Rami Kantor
Journal:  Clin Infect Dis       Date:  2015-01-30       Impact factor: 9.079

Review 4.  Antifungal stewardship considerations for adults and pediatrics.

Authors:  Rana F Hamdy; Theoklis E Zaoutis; Susan K Seo
Journal:  Virulence       Date:  2016-09-02       Impact factor: 5.882

5.  Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study.

Authors:  J M Lestner; A Versporten; K Doerholt; A Warris; E Roilides; M Sharland; J Bielicki; H Goossens
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

6.  Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India.

Authors:  Soumya Swaminathan; Geetha Ramachandran; Hemanth Kumar Agibothu Kupparam; Vasantha Mahalingam; Lakshmi Soundararajan; Bhavani Perumal Kannabiran; Poorana Ganga Devi Navaneethapandian; Ira Shah; Ramesh Karunaianandham; Rajasekaran Sikhamani
Journal:  J Antimicrob Chemother       Date:  2011-03-09       Impact factor: 5.790

7.  Treatment of pediatric HIV infection.

Authors:  Elisa A d'Oulx; Elena Chiappini; Maurizio de Martino; Pier-Angelo Tovo
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

8.  Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Authors:  Louisa Pollock; Laura Else; Goenke Poerksen; Elizabeth Molyneux; Peter Moons; Sarah Walker; William Fraser; David Back; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2009-10-06       Impact factor: 5.790

Review 9.  Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.

Authors:  Walter Dehority; Jacobo Abadi; Andrew Wiznia; Rolando M Viani
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 10.  Management of paediatric HIV-1 resistance.

Authors:  Ravindra K Gupta; Diana M Gibb; Deenan Pillay
Journal:  Curr Opin Infect Dis       Date:  2009-06       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.